Navigation Links
Designing Controls for siRNA ,,, Experiments


Because of its apparent specificity, reproducibility, and ease of use, RNAi technology is greatly accelerating the functional characterization of disease-relevant genes for drug discovery, target validation, and basic research efforts. To ensure the validity of RNAi data, however, proper experimental design and controls are needed. This article outlines some of the critical parameters for performing RNAi experiments in mammalian cultured cells.


Tips for Experimental Design

Carefully Choose Your siRNA Sequence for Maximum Specificity.
Although data indicate that siRNAs are highly specific, it is important to minimize the possibility of off-target effects by designing siRNAs that have limited sequence similarity to genes other than their intended target. Currently, it is not clearly understood how the number and location of mismatches between the antisense siRNA strand and the target mRNA affect silencing. Some reports indicate that a single mismatch in the center of an siRNA sequence can abolish silencing effects (1,2). In fact, this remarkable specificity has been shown in a model system to permit allele specific gene silencing (2). In contrast, another report indicates that siRNAs with regions of 14-15 contiguous bases of sequence similarity between the siRNA and an mRNA can induce silencing (3). Until we develop a better understanding of the specificity of siRNAs for their targets, it is best to design siRNAs that are completely complementary to the mRNA target and that contain at least 2 or more mismatches to all off target mRNAs. Also, results obtained with pools or populations of siRNAs should be confirmed with individual siRNAs to enhance the confidence level in the data.

Use the Minimum siRNA Concentration Required to Achieve Silencing.
Recent reports indicate that siRNA concentrations of 100 nM or higher in mammalian cultured cells can lead to nonspecific changes in gene expression (3,4). In general, transfecting 5-20 nM of an efficacious siRNA appears to minimize nonspecific effects while providing maximal target gene silencing. The concentration of siRNA required will depend upon the method and efficiency of siRNA delivery, the cell line used, and the effectiveness of the siRNA sequence.


Suggested Experimental Controls

Ambion scientists use and recommend a number of different controls for siRNA experiments. Most of these coincide with the suggested controls detailed in a recent editorial published in Nature Cell Biology (5). These controls can be used in virtually any gene silencing experiment, whether the effects are analyzed one gene at a time using more traditional mRNA and protein analysis techniques or on a genome-wide scale using microarrays.

Scrambled siRNA Control
A scrambled siRNA control is used to discount any changes to the gene expression profile that may result from the siRNA delivery method. Comparing cells transfected with a scrambled siRNA control to untransfected cells can reveal changes caused by siRNA delivery.

Positive siRNA Control
Ambion scientists always include a positive siRNA control in their experiments -- usually the Silencer GAPDH siRNA -- which serves to monitor siRNA transfection efficiency. When the positive control fails to elicit the expected reduction in gene expression, poor transfection is immediately suspected.

Multiple siRNAs to a Single Target
One of the best ways to increase confidence in data from siRNA experiments is to use two or more siRNAs to a single gene target. The siRNAs should first be analyzed for effectiveness at reducing target gene expression. Different siRNAs to the same gene with comparable gene silencing efficacy should induce similar changes in gene expression profile and phenotype. Any changes induced by one siRNA and not the other(s) could be attributed to off target effects. This approach is also valid for siRNA cocktails. In other words, cocktails prepared from different regions of the same gene can be used to confirm gene silencing results.

Monitor the Antiviral Response
Recent evidence indicates that up-regulation of the antiviral response may be a useful indicator of nonspecific siRNA effects. Although we do not yet routinely monitor the antiviral response in our own experiments, there are several published reports on how this response can be detected. One way is to assess levels of 2'5'-oligoadenylate synthetase mRNA (6). 2'5' oligoadenylate synthetase catalyzes the synthesis of 2'-5' polyadenylic acid, which activates the nonspecific ribonuclease RNase L. Another way is to monitor activation of the dsRNA-dependent protein kinase, PKR, which is involved in the type 1 interferon response. PKR phosphorylates the small subunit of the eukaryotic initiation factor 2-alpha (eIF2alpha), which results in nonspecific inhibition of translation. PKR activation can therefore be examined by monitoring the phosphorylation of eIF2alpha (7).

Monitor Both Target mRNA and Protein Levels
In siRNA experiments it may be beneficial to monitor both mRNA and protein levels for several reasons. For instance, mRNA reduction seen without a corresponding reduction in protein levels can indicate that protein turnover is slow. Furthermore, protein reduction in the absence of mRNA reduction may indicate that an siRNA is mediating its effects at the translational level like a microRNA.

The use of RNAi has enormous potential for analyzing gene function, elucidating biological pathways, and identifying and validating potential drug targets. The RNAi field is still in its infancy, and recommendations on experimental design and proper controls are likely to evolve. Ambion is committed to bringing researchers around the world the most up-to-date information on RNAi for their own research. For the latest information, see the RNAi Resource.


back to top


'"/>

Source:


Page: All 1 2 3 4 5

Related biology technology :

1. Designing a Successful qRT-PCR Experiment
2. Designing a Better siRNA
3. Housekeeping Genes: Universal Positive Controls in siRNA Knockdown Experiments
4. RNAi: The Controls You Need
5. Custom and library siRNA for efficient gene silencing
6. Custom and library siRNA for efficient gene silencing
7. Cancer siRNA Oligo Set Version 1.0
8. Library siRNA
9. Custom siRNA Oligo Synthesis Service
10. Efficient RNAi-mediated gene silencing in neuronal cells using QIAGEN siRNA and TransMessenger Transfection Reagent*
11. Quantification of siRNA Silencing Efficiency Using the LightCycler System
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Designing Controls for siRNA Experiments

(Date:4/21/2015)... DIEGO, CA (PRWEB) April 21, 2015 Whether ... in a lab, or bolted to a Kessler CineDrive ... stadium… or at the beach, the TS3-H is designed to ... Based on a brand-new state-of-the-art 5MP sensor, the TS5-H offers ... predecessors, with superior imaging characteristics. , According to Tom ...
(Date:4/20/2015)... Stent retriever thrombectomy, an endovascular technique ... brain reduced disability after stroke, according to a ... of the Society of Vascular and Interventional Neurology ... step forward that will change the way we ... Jovin, who is associate professor of Neurology and ...
(Date:4/20/2015)... (PRWEB) April 20, 2015 PMG ... its 12th clinical research site: PMG Research of Christie ... operation of the clinical research department at Christie ... the Southeast to a second region within the United ... physician practice enhances PMG’s access to an additional 80,000 ...
(Date:4/20/2015)... Calif. , April 20, 2015  Ardelyx, ... company focused on cardio-renal, gastrointestinal and metabolic diseases, ... MRCP, has joined the Company,s Board of Directors. ... and board level experience, having built and led ... development, regulatory approval and into healthcare systems globally. ...
Breaking Biology Technology:Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 2Fastec Imaging Releases the TS5-H High Definition High-Speed Camera 3SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 2SVIN President Tudor Jovin, MD, Co-Leads Groundbreaking Stroke Study In The New England Journal Of Medicine 3PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 2PMG Research Announces the Formation of its 12th Site in Champaign-Urbana, IL 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 2Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 3Ardelyx Appoints Dr. Annalisa Jenkins to Its Board of Directors 4
... II study of 20 patients reported in Annals ... Therapeutics, Inc.,(CTI) (Nasdaq: CTIC ; MTA) today ... of a limited phase II study of CHOP ... Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60,years of ...
... 4 Vermillion, Inc.,(Nasdaq: VRMLD ), a ... diagnostic test programs and provided a preview,of key ... course of 2008. The,Company also released financial results ... 2007., "In 2007, Vermillion made significant clinical ...
... a.m. Eastern/2:30 p.m. Central European/5:30 a.m. Pacific Time,members of Cell Therapeutics, Inc.,s (CTI) (Nasdaq: ... the company,s recent,transactions targeting cleaning up the capital structure, and upcoming,product and sales milestones., ... Conference Call Numbers ... Wednesday, ...
Cached Biology Technology:CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 2CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 3CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 2Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 3Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 4Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 5Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 6Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 7Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 8Vermillion Summarizes Recent Accomplishments and 2007 Financial Results; Outlines 2008 Business Milestones 9Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones 2
(Date:4/13/2015)... NEW YORK , April 13, 2015 /PRNewswire/ ... study by TechSci Research, "Global Biometrics Market Forecast & ... to register a CAGR of around 14% till ... various governments for large scale implementation and review ... technology and launch of new products with greater ...
(Date:4/10/2015)... , April 10, 2015 Research ... of the "Security Competitive Profiles - NEC" ... , NEC will continue to supply a ... the market, with a company focus on the development ... Winning opportunities in the Asia-Pacific ...
(Date:4/8/2015)... April 8, 2015  Infinisource, a leading provider ... and Morpho, a leading supplier of biometric identification ... the market,s most advanced biometrically-enabled time clock, the ... time clock is setting a bold, new standard ... for the small and mid-size employer. When connected ...
Breaking Biology News(10 mins):Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... working on the fundamental biological processes of plants could ... many parts of the world. Using model plant species, ... uncovered one of the processes used by the plants ... discoveries are now being applied to improve the productivity ...
... geochemists from the University of Southern California and Rice ... that could power spy drones that fit in the ... long been interested in micro-scale air vehicles ?some as ... the lack of a suitable, compact power source. With ...
... at the Max Planck Institute of Biochemistry in Martinsried, ... that blocking blood vessel development in a tumour slows ... principle led to the development of SUTENT®, whose active ... use in the United States, and it is expected ...
Cached Biology News:Sun protection for plants 2USC, Rice to develop bacteria-powered fuel cells 2Basic research leads to a novel cancer therapy 2Basic research leads to a novel cancer therapy 3Basic research leads to a novel cancer therapy 4
... MSC series of Class II Biological ... and certification to the world's highest ... that the cabinets cannot be adjusted ... lighting, low noise and arm rest ...
... Multidizer is designed with a variety of ... - all in one unit. Shake, rock, ... operating compartments allow for hybridization and blotting ... , The upper chamber uses a ...
... Jouan MSC series of Class II ... conditions and certification to the world's ... ensures that the cabinets cannot be ... Natural lighting, low noise and arm ...
... The Jouan RC Sensitive Bio (for heat-labile ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: